SYDNEY, Oct. 5, 2023
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX:
KZA), an oncology-focused drug development company, is pleased to
provide an update regarding upcoming data presentations at two
international scientific meetings, European Society for Medical
Oncology (ESMO) Congress 2023 and Society for Neuro-Oncology (SNO)
Annual Meeting. The presentations will highlight data for both
investigational clinical drugs, EVT801 and Paxalisib.
The presentations include:
ESMO Congress 2023 (Madrid,
Spain)
Title: VEGFR-3 expression profiling by histology and mRNA signature
to classify patient population for the selective VEGFR-3 inhibitor
EVT801
Presenter: Carlos A Gomez-Roca (IUCT-Oncopole, Toulouse, France)
Date: Saturday, 21 October 2023
Type: Poster Presentation
SNO Annual Meeting (Vancouver,
Canada)
Title: Phase 1 study of paxalisib and radiotherapy for CNS disease
harboring PI3K pathway mutations: pilot analysis of circulating
tumor DNA for patient eligibility confirmation and post treatment
response
Presenter: Brandon S. Imber
(Memorial Sloan Kettering Cancer Center, New York)
Date: Friday, 17 November 2023
Type: Poster Presentation
SNO Annual Meeting (Vancouver,
Canada)
Title: Combining ONC201 and paxalisib for the treatment of Diffuse
Midline Glioma (DIPG); the preclinical results underpinning the
international Phase II clinical trial (NCT05009992)
Presenter: Evangeline R. Jackson
(University of Newcastle,
Australia)
Date: Friday, 17 November 2023
Type: Plenary Oral Presentation
SNO Annual Meeting (Vancouver,
Canada)
Title: PNOC022: A combination therapy trial using an adaptive
platform design for patients with Diffuse Midline Gliomas (DMGs) at
initial diagnosis, post-radiation therapy and at time of
Progression
Presenter: Sabine Mueller
(University of California, San
Francisco)
Date: Sunday, 19 November 2023
Type: Oral Presentation
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an
oncology-focused drug development company, based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant inhibitor of
the PI3K / Akt / mTOR pathway, which is being developed to
treat multiple forms of brain cancer. Licensed from Genentech in
late 2016, paxalisib is or has been the subject of ten
clinical trials in this disease. A completed Phase II study
in glioblastoma reported promising signals of clinical
activity in 2021, and a pivotal study in glioblastoma,
GBM AGILE, is ongoing, with final data expected in CY2023.
Other clinical trials are ongoing in
brain metastases, diffuse midline gliomas
CNS lymphoma, with several, and primary
of these having reported encouraging interim
data.
Paxalisib was granted Orphan Drug Designation for glioblastoma
by the US FDA in February 2018, and
Fast Track Designation (FTD) for glioblastoma by the FDA in
August 2020. Paxalisib was also
awarded (FTD) in July 2023 for
the treatment of solid tumour brain metastases harbouring PI3K
pathway mutations in combination with radiation therapy. In
addition, paxalisib was granted Rare Pediatric Disease Designation
and Orphan Drug Designation by the FDA for diffuse intrinsic
pontine glioma in August 2020, and for atypical teratoid /
rhabdoid tumours (AT/RT) in June 2022
and July 2022, respectively.
Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed
from Evotec SE in April 2021.
Preclinical data has shown EVT801 to be active against a broad
range of tumour types and has provided compelling evidence of
synergy with immuno-oncology agents. A Phase I study commenced
recruitment in November 2021.
For more information, please
visit www.kaziatherapeutics.com or follow
us on Twitter @KaziaTx.
Forward-Looking Statements
This announcement may contain forward-looking statements, which
can generally be identified as such by the use of words such as
"may," "will," "estimate," "future," "forward," "anticipate," or
other similar words. Any statement describing Kazia's future
plans, strategies, intentions, expectations, objectives, goals or
prospects, and other statements that are not historical facts, are
also forward-looking statements, including, but not limited to,
statements regarding: the timing for results and data
related to Kazia's clinical and preclinical trials, and
Kazia's strategy and plans with respect to its programs, including
paxalisib and EVT801. Such statements are based on Kazia's current
expectations and projections about future events and future trends
affecting its business and are subject to certain risks and
uncertainties that could cause actual results to differ materially
from those anticipated in the forward-looking statements, including
risks and uncertainties: associated with clinical and preclinical
trials and product development, related to regulatory approvals,
related to Kazia's executive leadership changes, and related to the
impact of global economic conditions. These and other risks and
uncertainties are described more fully in Kazia's Annual Report,
filed on form 20-F with the SEC, and in subsequent filings with the
United States Securities and Exchange Commission. Kazia undertakes
no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or
otherwise, except as required under applicable law. You should not
place undue reliance on these forward-looking statements, which
apply only as of the date of this announcement.
This announcement was authorized for release by Dr John Friend, CEO, on behalf
of the Board of Directors.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-presentations-at-upcoming-scientific-meetings-301947951.html
SOURCE Kazia Therapeutics Limited